Latest Breaking News On - Sonnet biotherapeutics company profile - Page 1 : comparemela.com

Sonnet BioTherapeutics (SONN) Buy Rating Reaffirmed at Chardan Capital

Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report)‘s stock had its “buy” rating reiterated by analysts at Chardan Capital in a research note issued on Tuesday, Benzinga reports. They currently have a $30.00 price objective on the stock. Sonnet BioTherapeutics Stock Up 1.9 % Shares of Sonnet BioTherapeutics stock opened at $1.65 on Tuesday. The firm’s […]

Sonnet biotherapeutics holdings incSonnet biotherapeutics company profileGet free reportChardan capital

Sonnet BioTherapeutics (SONN) to Release Quarterly Earnings on Monday

Sonnet BioTherapeutics (NASDAQ:SONN – Get Free Report) will post its quarterly earnings results on Monday, February 12th. Sonnet BioTherapeutics Stock Up 2.7 % NASDAQ SONN opened at $1.51 on Friday. Sonnet BioTherapeutics has a one year low of $1.08 and a one year high of $26.40. The business has a 50 day simple moving average […]

Renaissance technologiesGeode capital managementSonnet biotherapeutics company profileSabby managementSonnet biotherapeutics holdings incGet free reportFunds managementCapital managementSonnet biotherapeuticsNasdaq sonn

Sonnet BioTherapeutics (SONN) Scheduled to Post Quarterly Earnings on Wednesday

Sonnet BioTherapeutics (SONN) Scheduled to Post Quarterly Earnings on Wednesday
theenterpriseleader.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from theenterpriseleader.com Daily Mail and Mail on Sunday newspapers.

Geode capital managementRenaissance technologiesSabby managementSonnet biotherapeutics company profileSonnet biotherapeutics holdings incGet free reportFunds managementCapital management

Sonnet BioTherapeutics (NASDAQ:SONN) Coverage Initiated at LADENBURG THALM/SH SH

LADENBURG THALM/SH SH assumed coverage on shares of Sonnet BioTherapeutics (NASDAQ:SONN – Free Report) in a report released on Monday morning, Benzinga reports. The firm issued a buy rating on the stock. Separately, Chardan Capital cut their price objective on Sonnet BioTherapeutics from $308.00 to $264.00 and set a buy rating for the company in […]

Boothbay fund managementGeode capital managementVirtu financialSigma securitiesSonnet biotherapeutics company profileSonnet biotherapeutics holdings incFree reportChardan capitalStreet corpFund managementCapital managementGet free reportSonnet biotherapeuticsNasdaq sonnInitiated coverageLadenburg thalm sh

Sonnet BioTherapeutics Holdings, Inc (NASDAQ:SONN) Short Interest Update

Sonnet BioTherapeutics Holdings, Inc. (NASDAQ:SONN – Get Free Report) was the recipient of a significant decline in short interest during the month of July. As of July 31st, there was short interest totalling 356,700 shares, a decline of 39.4% from the July 15th total of 588,400 shares. Based on an average daily volume of 3,840,000 […]

Sonnet biotherapeutics company profileEf hutton acquisition coVirtu financialBoothbay fund managementGeode capital managementRenaissance technologiesSonnet biotherapeutics holdings incGet free reportStreet corpFund managementCapital managementSonnet biotherapeuticsNasdaq sonn